This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

William S. Evans, MD; James N. Bowen, DO; Frank L. Giordano, MD; Bruce Clark, PharmD
Tripler Army Medical Center Tripler AMC, Hawaii

JAMA. 1985;253(15):2191-2192.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Stadol (butorphanol tartrate) was introduced in 1978 as a potent synthetic opiate agonist-antagonist indicated for the relief of moderate to severe pain. The official package circular reproduced in the Physician's Desk Reference notes that, "even though Stadol has a low physical dependence liability, care should be taken that individuals who may be prone to drug abuse are closely supervised." Stadol is handled as a nonscheduled drug and only routine security measures are taken with its storage and distribution. A recent case that we treated led us to question the wisdom of this policy.

Report of a Case.—

The patient was a staff member of our institution who underwent surgical excision of a salivary gland approximately eight months before admission to our service. The patient's postoperative pain was treated with meperidine hydrochloride (Demerol) given in 50-mg doses intramuscularly every six hours for a total of three doses. The . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?